Therefore, inhibiting the binding of CCL17 to CCR4 may prevent Th2 cells from migrating to inflammatory tissues and make CCR4 and CCL17 a potential target for the treatment of AD. This evidence concerns the gene CCR4 and Alzheimer disease.